Navigation Links
IRIDEX MicroPulse™ Laser Therapy Enhances Visual Function in Patients with Central Serous Chorioretinopathy (CSC)
Date:1/25/2012

MOUNTAIN VIEW, Calif., Jan. 25, 2012 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) announced results of a clinical study evaluating the use of IRIDEX' MicroPulse laser therapy.  The study examined the tissue-sparing therapy's effectiveness with patients diagnosed with central serous chorioretinopathy (CSC).(1) The study concluded tissue-sparing subvisible MicroPulse laser is superior to anti-VEGF injections for CSC, also known as CSR, an eye disease, which results in blurred vision typically perceived as a dark spot in the center of the field of vision. It primarily affects men between the ages of 20-50 and is often associated with type-A personalities.

"Because of the absence of laser-induced retinal damage discernable at any time postoperatively, subvisible MicroPulse photocoagulation, with no focal burn end point (or its consequences), represents an elegant medical approach and a true clinical alternative," stated co-author Prof. Frank Koch, head of the vitreo-retinal department at the University Eye Clinic of Johann Wolfgang Goethe University in Frankfurt, Germany.

"MicroPulse laser therapy is producing the kind of clinical results that we believe will fuel a paradigm shift in the treatment of retinal diseases,"  Dr. Dominik Beck President & CEO stated. "MicroPulse is a tissue-sparing therapy that we believe brings long-term therapeutic benefits with no collateral damage and can increase visual function in a very cost-effective manner. Causing no collateral damage at any time postoperatively allows for MicroPulse applications to be delivered over the entire area of CSC leakage including those near to and directly over the center of the macula (the fovea). This is a powerful vote for safety. While CSC does not impact a large population, this study is additional clinical evidence of the efficacy and safety in using MicroPulse laser therapy to treat a broader class of retinal diseases that impacts millions of Americans."

This was the first comparative, prospective evaluation of subvisible MicroPulse laser treatment and anti-VEGF injections in the treatment of CSC with regard to changes in subretinal fluid and visual function. The results indicated superior subretinal fluid resolution for MicroPulse laser compared to anti-VEGF injections, and superior improvement in visual acuity and other visual functions.

(1) Koss MJ, Beger I, Koch FH. Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy. Eye (Lond) 2011. Advanced online publication

About MicroPulse Technology

MicroPulse is a tissue-sparing laser therapy that works by electronically "chopping" a continuous-wave laser emission into trains of microsecond pulses. This enhances the physician's ability to more precisely control the laser effects on target tissues, offering treatment with less collateral effects than conventional, continuous-wave laser photocoagulation.

About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems and delivery devices. We provide solutions for multiple specialties, including ophthalmology, otolaryngology, veterinary, and dermatology. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company's website at http://www.iridex.com/

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to MicroPulse laser therapy and its impact on the treatment of retinal diseases. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 1, 2011 and our Quarterly Reports on Form 10-Q for the fiscal quarters ended April 2, 2011, July 2, 2011 and October 1, 2011, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

 

 

 


'/>"/>
SOURCE IRIDEX Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. IRIDEX to Present at the Sidoti & Company New York Micro Cap Conference
2. Cutera and IRIDEX Announce Acquisition of IRIDEX Aesthetic Business Unit
3. 10-Year Study Demonstrates IRIDEX MicroPulse™ Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema
4. IRIDEX Signs License and Distribution Agreement with Leader in Eye Care
5. IRIDEX Reports 2011 Third Quarter and Nine-Month Results
6. IRIDEX Announces Third Quarter 2011 Conference Call and Release Date
7. IRIDEX Launches New MicroPulse™ Module Targeting the Broad Ophthalmology Laser Photocoagulation Market
8. IRIDEX Names Veteran Healthcare Executive Dominik Beck President, CEO
9. IRIDEX Licenses the Exclusive Rights to Ophthalmology Products and Intellectual Property from Ocunetics, Inc.
10. IRIDEX Expands ENT Laser Applications
11. IRIDEX Reports Growing Revenue and Profits in 2011 First Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... , Dec. 3, 2016   Pairnomix, LLC, ... Medicine Alliance (PEPMA) recognized by the White House, today announced ... approach to the identification of candidate therapies for a patient ... SCN8A gene were presented at the 70 th ... Houston, TX , December 2-6, 2016.  ...
(Date:12/2/2016)... Research and Markets has announced the addition of the ... ... R&D Drug Pipeline Database: 1-Year Subscription ... provides 24/7 online access to information about more than 21,000 project ... drug candidates in research & development. Pre-established and ...
(Date:12/2/2016)... the ECG Cables And ECG Leadwires Market owing to the ... On the other hand, the Asia-Pacific ... during the forecast period. The market players namely, ... ( Ireland ), Koninklijke Philips N.V. ( ... China ), held major share of the ECG ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. ... Mediaplanet, Dr. Murthy explains how he was inspired to practice medicine at an early ... medicine is about more than making diagnoses and prescribing medicine,” he states. “It is ...
(Date:12/2/2016)... , ... December 02, 2016 , ... More than half ... while 84 percent of parents report speaking with their child about sex related topics, ... transmitted diseases. , Mediaplanet is proud to announce the launch of its second edition ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical Systems, Inc. (UMS) ... first company to offer robotic imaging to veterinary medicine is sponsoring the appearance ... for the American Association of Equine Practitioners 62nd Annual Convention from December 4-6, ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is ... create versatile lower third titles with just a few clicks of the mouse," said ... includes 30 lower third animations. Choose from various styles with accented animations, rigid boxes, ...
(Date:12/2/2016)... ... 02, 2016 , ... Date aired: November 28, 2016 , ... The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein , Sharon Kleyne, America’s leading water ... Change and Your Health radio program syndicated on Voice of America, welcomed author ...
Breaking Medicine News(10 mins):